---
title: "Kanion Pharmaceutical: Clinical trial for Jianpi Shugan Guben Granules approved"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253428236.md"
description: "According to the Zhitong Finance APP, Kanion Pharmaceutical announced that the company has received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration for the Jianpi Shugan Guben Granules. The relevant drug is Jianpi Shugan Guben Granules, indicated for diarrhea-type irritable bowel syndrome with liver stagnation and spleen deficiency"
datetime: "2025-08-18T09:19:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253428236.md)
  - [en](https://longbridge.com/en/news/253428236.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253428236.md)
generator: "portal-rs"
---

# Kanion Pharmaceutical: Clinical trial for Jianpi Shugan Guben Granules approved

According to the Zhitong Finance APP, Kanion Pharmaceutical (600557.SH) announced that the company has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration for the product Jianpi Shugan Guben Granules. The indication for this drug is diarrhea-type irritable bowel syndrome with liver stagnation and spleen deficiency

### Related Stocks

- [600557.CN](https://longbridge.com/en/quote/600557.CN.md)

## Related News & Research

- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [Cocoa Prices Fall on Rising Nigerian Cocoa Exports](https://longbridge.com/en/news/296637826.md)
- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [Weekly Recap: 10,000 H200 chips, export limits and HK$300.5m buyback](https://longbridge.com/en/news/296712694.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**